DGCI likely to grant market approval for Covaxin & Covishield at THESE prices - Details inside - The Central Drugs Standard Control Organisation s Subject Expert Committee suggested granting regular market approval to COVID-19 vaccines
Congress leader Shashi Tharoor said that the approval was premature and could be dangerous. Covishield by SII and Covaxin by Bharat Biotech got the DCGI nod for restricted use .
New Delhi: The Drugs Controller General of India (DCGI) on Sunday granted emergency use approval to Serum Institute of India (SII) and Bharat Biotech for their COVID-19 vaccines. Covishield by SII and Covaxin by Bharat Biotech got the DCGI nod for restricted use .
Congratulating the country over the same, Prime Minister Narendra Modi said: A decisive turning point to strengthen a spirited fight! DCGI granting approval to vaccines of @SerumInstIndia and @BharatBiotech accelerates the road to a healthier and COVID-free nation. Congratulations India. Congratulations to our hardworking scientists and innovators.